|
|
 |
|
Viewing report
|
|
|
|
Realizing the Promise of Therapeutic RNAi: Emerging Strategies for RNAi Delivery
Decision Resources, Inc., Jan 2008, Pages: 26
Introduction
The discovery of RNA interference (RNAi) has renewed interest in developing nucleic acid drugs based on targeting messenger RNAs (mRNAs). This field of research offers the potential to produce low-dose, nontoxic RNAi agents to treat important diseases. Venture capitalists have invested large sums of money in RNAi companies, and Big Pharma is acquiring and partnering with RNAi specialty companies. The success of RNAi therapeutics rests on the development of technologies that can deliver these agents to their targets.
Questions Answered in This Report:
- Several companies are focusing on RNAi-based therapeutics. Which are the leading companies in the field, and which ones are in partnership with or have been acquired by Big Pharma? What projects are they undertaking?
- The holy grail for RNAi drug companies remains systemic delivery. Companies are competing furiously to develop viable systemic delivery methods. What are the promising technologies for systemic delivery, and which companies are at the forefront of delivery technology?
- Opko Health’s bevasiranib is the most advanced RNAi therapeutic. It is in Phase III clinical trials for wet age-related macular degeneration. What other RNAi therapeutics have been developed and for what disease(s)? At what stage of development are they?
Scope:
- SRNAi: Its mechanism of action.
- Delivery of RNAi therapeutics: Direct delivery of naked siRNA, systemic delivery of siRNA using stable nucleic acid lipid particles (SNALPs), lipidoid nanoparticles, siRNA-lipoplexes, interfering nanoparticles, TargeTran nanoparticles, covalent conjugation of siRNA to a targeting molecule, antibody - mediated targeting of siRNAs, systemic targeting of siRNAs to the CNS.
- Top companies in RNAi research: Alnylam Pharmaceuticals, Sirna Therapeutics, RXi Pharmaceuticals, Silence Therapeutics.
Customers who bought this item also bought
RNAi - Technologies, Markets and Companies
Outlook for RNAi, 2007: siRNA and miRNA in Biology, Diagnostics and Therapeutics
RNAi 2008
RNAi Therapeutics 2008 Market Report
The Outlook For RNAi: Accelerating Drug Discovery and the Development of RNAi Therapeutics
The Future of RNAi Therapeutics: Drug Pipelines and Prospects
RNA Interference Markets
RNAi: Broad Application, Expansive Opportunity, 2nd Edition
Alnylam & Roche RNAi Therapeutics Strategic Alliance Agreement Call - Alnylam Pharmaceuticals, Inc. - Earnings Transcript
RNA Interference for Drug R&D: Applications, Alliances, Companies and WW Market to 2011
Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities
Drug Delivery in Cancer - Technologies, Markets and Companies
|
|
|
|
